| 1 |
30391349 | Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment. | 2019 Jan 5 |
1 |
| 2 |
29566599 | Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells. | 2018 Oct |
1 |
| 3 |
27013225 | Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer. | 2016 |
1 |
| 4 |
24879994 | SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. | 2014 Jul 18 |
2 |
| 5 |
25227799 | Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer. | 2014 |
1 |
| 6 |
23629654 | Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. | 2013 Jun 14 |
1 |
| 7 |
23630365 | Potent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo. | 2013 Aug 1 |
1 |
| 8 |
17131314 | Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. | 2007 Feb 15 |
1 |
| 9 |
17230513 | Inhibition of heat shock protein-90 modulates multiple functions required for survival of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells. | 2007 Apr 15 |
1 |
| 10 |
17363505 | Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. | 2007 Mar |
1 |
| 11 |
17949452 | Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. | 2007 Dec |
1 |
| 12 |
16213582 | The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. | 2006 May |
1 |
| 13 |
16384610 | Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. | 2006 Apr 15 |
1 |
| 14 |
16544941 | Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. | 2006 Mar |
1 |
| 15 |
16634649 | Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. | 2006 May 2 |
2 |
| 16 |
16860662 | Inhibitors of the HSP90 molecular chaperone: current status. | 2006 |
1 |
| 17 |
17108135 | Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. | 2006 Nov 15 |
1 |
| 18 |
15804996 | The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells. | 2005 Mar |
2 |
| 19 |
15853661 | Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. | 2005 |
1 |
| 20 |
20641498 | 68Ga-Trastuzumab F(ab’) fragment | 2004 |
1 |
| 21 |
12617036 | [Molecular chaperone HSP90 as a novel target for cancer chemotherapy]. | 2003 Jan |
1 |
| 22 |
12810654 | Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. | 2003 Jun 15 |
2 |
| 23 |
12036925 | Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. | 2002 Jun 1 |
1 |
| 24 |
11358819 | Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. | 2001 May 15 |
1 |